- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02734472
Blood Pressure Follow-up Study in Two Chinese Cohorts(C-BPCS) (C-BPCS)
Effect of the Interaction Between Environmental Factors and Genetic Predisposition on Long-term Blood Pressure in Chinese Population
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710061
- Recruiting
- First Affiliated Hospital of Xi'an JiaoTong University
-
Contact:
- Jianjun Mu, doctor
- Phone Number: 0086-029-85323804
- Email: mujjun@163.com
-
Contact:
- Chao chu, master
- Phone Number: 0086-029-85323800
- Email: iaacd@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
In March and April, 1987, investigators established the cohort of Hanzhong Adolescent Hypertension Study. A total of 4,623 adolescents aged 6-15 years old in over 20 schools of three towns (Qili, Laojun and Shayan) in Hanzhong, Shaanxi, China were recruited.
In 2003-2004, investigators established the cohort of Mei county adult salt sensitive hypertension Study. This study was a family-based dietary intervention study conducted in a Han Chinese population from rural areas of northern China. A total of 675 subjects from 126 families were recruited in this cohort.
Description
Inclusion Criteria:
Hanzhong cohort of Adolescent Hypertension Study:
- adolescents aged 6-15 years old in over 20 schools of three towns (Qili, Laojun and Shayan) in Hanzhong, Shaanxi, China.
Mei county cohort of adult salt-sensitive hypertension study:
- Han individuals in rural northern China
- adults aged 18-60 years
- individuals who had a mean systolic BP (SBP) between 130-160 mmHg and/or a diastolic BP (DBP) between 85-100 mmHg and no use of antihypertensive medications were identified as the proband
- the probands'parents,siblings, spouses, and offspring were recruited for the study.
Exclusion Criteria:
During the follow-up period, the exclusion criteria are as follows:
- Secondary hypertension
- a history of severe cardiovascular disease
- chronic kidney disease or liver disease
- unable to complete the examination
- unable/refuse to sign the informed consent form
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Hanzhong cohort
A total of 4623 adolescents aged 6-15 years old in Hanzhong rural areas were recruited in 1987.During the follow-up period, the information about the incidence and risk factors of hypertension will be collected.
|
During the follow-up period,General information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters(Lipid, hsCRP levels, etc)and other laboratory examination parameters(arterial stiffness,IMT, FMD) will be collected.
|
|
Mei county cohort
A total of 675 individuals from 126 families were recruited in this family-based dietary intervention study.
A community-based BP screening was conducted among adults aged 18-60 years in the study villages.
The probands who had a mean systolic BP (SBP) between 130-160 mmHg and/or a diastolic BP (DBP) between 85-100 mmHg and no use of antihypertensive medications and their parents, siblings, spouses, and offspring were recruited in this study.
During the follow-up period, the information about the incidence and risk factors of hypertension will be collected.
|
During the follow-up period,General information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters(Lipid, hsCRP levels, etc)and other laboratory examination parameters(arterial stiffness,IMT, FMD) will be collected.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
blood pressure value(mmHg)
Time Frame: First day of the three-day follow-up period
|
The follow-up study of these two cohorts will last approximately 18 months (Jul 2016 to Dec 2017).
During this period, each subject will receive a three-day follow-up examination.
Three BP(mmHg) measurements will be obtained using a mercury sphygmomanometer on the first day of the three-day follow-up period.
|
First day of the three-day follow-up period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Left ventricular hypertrophy(g/m^2)
Time Frame: During the three-day follow-up period
|
The follow-up study of these two cohorts will last approximately 18 months (Jul 2016 to Dec 2017).
During this period, each subject will receive a three-day follow-up examination.
Left ventricular mass index (LVMI,g/m^2)will be measured using echocardiography during the three-day follow-up period.
|
During the three-day follow-up period
|
|
Increased arterial stiffness(mm/s)
Time Frame: During the three-day follow-up period
|
The follow-up study of these two cohorts will last approximately 18 months (Jul 2016 to Dec 2017).During this period, each subject will receive a three-day follow-up examination.
Brachial-ankle pulse wave velocity(baPWV,mm/s)will be measured with Noninvasive automatic waveform analyzer during the three-day follow-up period.
|
During the three-day follow-up period
|
|
Carotid artery wall thickening(mm)
Time Frame: During the three-day follow-up period
|
The follow-up study of these two cohorts will last approximately 18 months (Jul 2016 to Dec 2017).During this period, each subject will receive a three-day follow-up examination.
Carotid Intima media thickness (IMT,mm)will be measured using Color Doppler Ultrasound Diagnostic System during the three-day follow-up period.
|
During the three-day follow-up period
|
|
Microalbuminuria(mg/24h)
Time Frame: Second day of the three-day follow-up period
|
The follow-up study of these two cohorts will last approximately 18 months (Jul 2016 to Dec 2017).During this period, each subject will receive a three-day follow-up examination.
On the second day,24-hour urinary will be collected and the concentrations of microalbuminuria in the urine sample will be measured with Hitachi biochemical analyzer.The 24-h microalbuminuria(mg/24h)of each subject is calculated as the concentration of microalbuminuria multiplied by the 24-h urine volume of each individual.
|
Second day of the three-day follow-up period
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jianjun Mu, doctor, First Affiliated Hospital Xi'an Jiaotong University
Publications and helpful links
General Publications
- Mu J, Zheng S, Lian Q, Liu F, Liu Z. Evolution of blood pressure from adolescents to youth in salt sensitivies: a 18-year follow-up study in Hanzhong children cohort. Nutr J. 2012 Sep 14;11:70. doi: 10.1186/1475-2891-11-70.
- Liu F, Zheng S, Mu J, Chu C, Wang L, Wang Y, Xiao H, Wang D, Cao Y, Ren K, Liu E, Yuan Z. Common variation in with no-lysine kinase 1 (WNK1) and blood pressure responses to dietary sodium or potassium interventions- family-based association study. Circ J. 2013;77(1):169-74. doi: 10.1253/circj.cj-12-0900. Epub 2012 Oct 12.
- Niu ZJ, Yao S, Zhang X, Mu JJ, Du MF, Zou T, Chu C, Liao YY, Hu GL, Chen C, Wang D, Ma Q, Yan Y, Jia H, Wang KK, Sun Y, Yan RC, Man ZY, Ren DF, Wang L, Gao WH, Li H, Wu YX, Li CH, Gao K, Zhang J, Yang TL, Wang Y. Associations of genetic variations in NEDD4L with salt sensitivity, blood pressure changes and hypertension incidence in Chinese adults. J Clin Hypertens (Greenwich). 2022 Oct;24(10):1381-1389. doi: 10.1111/jch.14566. Epub 2022 Aug 30.
- Yuan Y, Mu JJ, Chu C, Zheng WL, Wang Y, Hu JW, Ma Q, Yan Y, Liao YY, Chen C. Effect of metabolically healthy obesity on the development of arterial stiffness: a prospective cohort study. Nutr Metab (Lond). 2020 Jul 2;17:50. doi: 10.1186/s12986-020-00474-8. eCollection 2020.
- Yuan Y, Chu C, Zheng WL, Ma Q, Hu JW, Wang Y, Yan Y, Liao YY, Mu JJ. Body Mass Index Trajectories in Early Life Is Predictive of Cardiometabolic Risk. J Pediatr. 2020 Apr;219:31-37.e6. doi: 10.1016/j.jpeds.2019.12.060. Epub 2020 Feb 12.
- Yuan Y, Hu JW, Wang Y, Wang KK, Zheng WL, Chu C, Ma Q, Yan Y, Liao YY, Mu JJ. Association between atherogenic index of plasma and subclinical renal damage over a 12-year follow-up: Hanzhong adolescent hypertension study. Eur J Clin Nutr. 2020 Feb;74(2):278-284. doi: 10.1038/s41430-019-0530-x. Epub 2019 Nov 14.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- XJTU1AF-CRF-2015-006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
BackBeat Medical IncNot yet recruitingHypertension, Systolic | Hypertension (HTN) | Heart Failure With Preserved Ejection Fraction (HFpEFGeorgia
-
Xuanwu Hospital, BeijingNot yet recruiting
-
Shenzhen Salubris Pharmaceuticals Co., Ltd.Not yet recruiting
-
Instituto de Cardiologia do Rio Grande do SulCompletedHypertension (HTN) | Hypertension ArterialBrazil
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
Abant Izzet Baysal UniversityNot yet recruitingPRIMARY HYPERTENSIONTurkey (Türkiye)
-
SingHealth PolyclinicsNanyang PolytechnicEnrolling by invitationHypertension,EssentialSingapore
-
Hacettepe UniversityBozok UniversityCompletedHypertension | Arterial Hypertension | Systemic HypertensionTurkey (Türkiye)
Clinical Trials on Incidence and risk factors of hypertension
-
First Affiliated Hospital Xi'an Jiaotong UniversityNot yet recruiting
-
Hospices Civils de LyonCompletedSeizures | Hyponatremia | BronchiolitisFrance
-
Centre Hospitalier Universitaire, AmiensUnknownRisk Factor | Inhalation PneumoniaFrance
-
Anna NordströmUmeå UniversityUnknownCardiovascular Diseases | Cancer | Fracture
-
Ottawa Hospital Research InstituteThe Physicians' Services Incorporated Foundation; Australian National UniversityCompletedHypertension | Diabetes | Infants Small for Gestational AgeCanada
-
Universidad de ConcepcionUniversidad Central del EcuadorCompletedQuality of Life | Hypertension | Menopause | Obesity, AbdominalEcuador
-
Turkish Neonatal SocietyCompletedNecrotizing EnterocolitisTurkey
-
Hospices Civils de LyonActive, not recruitingB Cell Lymphoma | Acute Kidney Injury (AKI) | Infusion of CD19 CAR T CellFrance
-
hadeer ehabCompletedInappropriate Prescribing | Clinical Oncology
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedBreast Carcinoma | Fallopian Tube Carcinoma | Ovarian Neoplasm | Primary Peritoneal CarcinomaUnited States